Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 5
1991 2
1992 6
1993 17
1994 50
1995 54
1996 48
1997 45
1998 62
1999 66
2000 77
2001 97
2002 97
2003 105
2004 113
2005 143
2006 108
2007 90
2008 107
2009 111
2010 102
2011 113
2012 85
2013 80
2014 81
2015 61
2016 68
2017 73
2018 76
2019 72
2020 71
2021 66
2022 50
2023 61
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

2,276 results

Results by year

Filters applied: . Clear all
Page 1
Expanded table: statins.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2019 Sep 23;61(1581):e152. Med Lett Drugs Ther. 2019. PMID: 31599870 Review. No abstract available.
Pravastatin for lowering lipids.
Adams SP, Alaeiilkhchi N, Tasnim S, Wright JM. Adams SP, et al. Cochrane Database Syst Rev. 2023 Sep 18;9(9):CD013673. doi: 10.1002/14651858.CD013673.pub2. Cochrane Database Syst Rev. 2023. PMID: 37721222 Review.
This represented a dose-response slope that was less than the other studied statins: atorvastatin, rosuvastatin, fluvastatin, pitavastatin and cerivastatin. From other systematic reviews we conducted on statins for its effect to reduce LDL cholesterol, pravastatin is simil …
This represented a dose-response slope that was less than the other studied statins: atorvastatin, rosuvastatin, fluvastatin, pitavas …
Fluvastatin.
Lawrence JM, Reckless JP. Lawrence JM, et al. Expert Opin Pharmacother. 2002 Nov;3(11):1631-41. doi: 10.1517/14656566.3.11.1631. Expert Opin Pharmacother. 2002. PMID: 12437496 Review.
Fluvastatin was the first wholly synthetic statin to the market and is effective in reducing total and low density lipoprotein cholesterol, which translates into reductions in coronary heart disease events. ...There have been no reports of fatal rhabdomyolysis to date. The …
Fluvastatin was the first wholly synthetic statin to the market and is effective in reducing total and low density lipoprotein choles …
Enantiospecific Pharmacogenomics of Fluvastatin.
Hirvensalo P, Tornio A, Neuvonen M, Kiander W, Kidron H, Paile-Hyvärinen M, Tapaninen T, Backman JT, Niemi M. Hirvensalo P, et al. Clin Pharmacol Ther. 2019 Sep;106(3):668-680. doi: 10.1002/cpt.1463. Epub 2019 May 14. Clin Pharmacol Ther. 2019. PMID: 30989645 Free PMC article.
A candidate gene analysis suggested that CYP2C9*2 also affects the AUC of both fluvastatin enantiomers and that SLCO2B1 single-nucleotide variations may affect the AUC of 3S,5R-fluvastatin. Thus, SLCO transporters have enantiospecific effects on fluvastatin p …
A candidate gene analysis suggested that CYP2C9*2 also affects the AUC of both fluvastatin enantiomers and that SLCO2B1 single-nucleo …
Statins protect mice from high-decibel noise-induced hearing loss.
Dépreux F, Czech L, Young H, Richter CP, Zhou Y, Whitlon DS. Dépreux F, et al. Biomed Pharmacother. 2023 Jul;163:114674. doi: 10.1016/j.biopha.2023.114674. Epub 2023 Apr 21. Biomed Pharmacother. 2023. PMID: 37435721 Free article.
The pump was filled with a solution of 50 M fluvastatin+carrier or with the carrier alone for continuous delivery to the cochlea. ...Threshold elevations were smaller in mice treated with noise+fluvastatin to about 2-, 6-, 20-,12- and 12-dB respectively. Survival of …
The pump was filled with a solution of 50 M fluvastatin+carrier or with the carrier alone for continuous delivery to the cochlea. ... …
Fluvastatin-induced rhabdomyolysis.
Modi JR, Cratty MS. Modi JR, et al. Ann Pharmacother. 2002 Dec;36(12):1870-4. doi: 10.1345/aph.1C029. Ann Pharmacother. 2002. PMID: 12452746
OBJECTIVE: To demonstrate a case of rhabdomyolysis with acute renal failure in a patient receiving fluvastatin and to present evidence that this was an adverse drug reaction to fluvastatin. ...CONCLUSIONS: Fluvastatin was the precipitating factor causing rhab …
OBJECTIVE: To demonstrate a case of rhabdomyolysis with acute renal failure in a patient receiving fluvastatin and to present evidenc …
Clinical pharmacokinetics of fluvastatin.
Scripture CD, Pieper JA. Scripture CD, et al. Clin Pharmacokinet. 2001;40(4):263-81. doi: 10.2165/00003088-200140040-00003. Clin Pharmacokinet. 2001. PMID: 11368292 Review.
The nonspecific CYP inducer rifampicin (rifampin) significantly increases fluvastatin oral clearance. In addition to being a CYP2C9 substrate, fluvastatin demonstrates inhibitory effects on this isoenzyme in vitro and in vivo. ...There are inadequate data evaluating …
The nonspecific CYP inducer rifampicin (rifampin) significantly increases fluvastatin oral clearance. In addition to being a CYP2C9 s …
Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer.
Bi YY, Chen Q, Yang MY, Xing L, Jiang HL. Bi YY, et al. Nat Commun. 2024 Mar 29;15(1):2759. doi: 10.1038/s41467-024-47080-3. Nat Commun. 2024. PMID: 38553451 Free PMC article.
Encouragingly, we find that the combination of cisplatin and fluvastatin can alleviate this problem. Therefore, we synthesize Fluplatin, a prodrug consisting of cisplatin and fluvastatin. ...
Encouragingly, we find that the combination of cisplatin and fluvastatin can alleviate this problem. Therefore, we synthesize Fluplat …
Exploring synergy between azole antifungal drugs and statins for Candida auris.
Halliday C, Kim HY, Tay E, Chen SCA, Alffenaar JW. Halliday C, et al. J Antimicrob Chemother. 2023 Dec 1;78(12):2824-2829. doi: 10.1093/jac/dkad303. J Antimicrob Chemother. 2023. PMID: 37823357 Free PMC article.
OBJECTIVES: Our study investigated potential synergy between the statins (rosuvastatin and fluvastatin) and azoles (voriconazole, posaconazole and isavuconazole) on clinical isolates of C. auris. ...Combination of azoles with fluvastatin showed synergy in 70%-90% of …
OBJECTIVES: Our study investigated potential synergy between the statins (rosuvastatin and fluvastatin) and azoles (voriconazole, pos …
2,276 results